Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
GY
Gyre Therapeutics, Inc. Common Stock
GYRE
Mkt Cap
$645.7M
Volume
131.00K
Next Earnings
November 6th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
GY
GYRE
GY
Gyre Therapeutics, Inc. Common Stock
GYRE
News
·
Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company
Mkt Cap
$644.7M
Volume
131.00K
Next Earnings
November 6th
Chart
Financials
Earnings
News
About
Insider
Filings
Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company
Gyre Therapeutics has completed its all-stock acquisition of Cullgen Inc. for approximately $300 million, creating a fully integrated biopharmaceutical company with U.S. and China operations. The combined entity will have a commercial-stage product (ETUARY® for lung fibrosis) and a robust pipeline focused on fibrosis and inflammatory diseases, including the lead candidate F351 for liver fibrosis. Dr. Ying Luo, former CEO of Cullgen, becomes President and CEO of the combined company.
Benzinga · May 4, 2026
Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Gyre Therapeutics reported full-year 2025 revenue of $116.6 million, up 10% year-over-year, within guidance. The company achieved alignment with China's CDE on conditional approval pathway for Hydronidone with NDA submission expected in H1 2026. Gyre completed enrollment in a Phase 3 pirfenidone pneumoconiosis trial and announced an agreement to acquire Cullgen for approximately $300 million to expand its targeted protein degradation platform. However, 2026 revenue guidance of $100.5-$111.0 million represents a 4.8-13.8% decline, reflecting a transition period prioritizing regulatory activities.
GlobeNewswire Inc. · Mar 12, 2026
Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update
Gyre Therapeutics reported Q3 2025 net income of $5.9 million, with quarterly revenue of $30.6 million, up 20% year-over-year. The company revised full-year revenue guidance to $115-118 million due to delayed product rollouts and procurement uncertainties.
GlobeNewswire Inc. · Nov 7, 2025
Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025
Gyre Therapeutics will present positive Phase 3 clinical trial results for Hydronidone, a novel anti-fibrotic agent targeting liver fibrosis in chronic hepatitis B, at AASLD's The Liver Meeting® 2025 in Washington D.C.
GlobeNewswire Inc. · Oct 14, 2025
Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors
Gyre Therapeutics announced the appointment of Dr. Dan Weng to its Board of Directors, bringing nearly four decades of clinical trial management experience. The company is focused on developing fibrosis treatments and has a prominent product in the Chinese market.
GlobeNewswire Inc. · Aug 22, 2025
Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China
Gyre Therapeutics announced the first dosing in a Phase 1 clinical trial of its novel drug F230 for the treatment of pulmonary arterial hypertension (PAH) in China. This milestone marks Gyre's entry into the PAH field, a rare and high-mortality condition with limited treatment options.
GlobeNewswire Inc. · Jun 10, 2025
Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock
Gyre Therapeutics, a biotechnology company, announced the pricing of its public offering of 2,222,222 shares of common stock at $9.00 per share, with an option for underwriters to purchase an additional 333,333 shares. The company plans to use the net proceeds to advance its clinical trial and for general corporate purposes.
GlobeNewswire Inc. · May 23, 2025
Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology
Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology
GlobeNewswire Inc. · Jun 18, 2024
Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® Indexes
Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® Indexes
GlobeNewswire Inc. · May 28, 2024
Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire Inc. · May 9, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
GY
GYRE
Gyre Therapeutics, Inc. Common Stock
Buy
Sell
Market
Limit
Soon
GYRE
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any GYRE yet.
Related Tickers
Earnings